Treatment for refractory lupus nephritis: Rituximab vs triple target therapy

Affiliations

¹ Department of Autoimmune Diseases, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Catalonia, Spain. Electronic address: rcervera@clinic.cat.
² Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
³ Department of Autoimmune Diseases, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Catalonia, Spain.
⁴ Instituto de Investigación Hospital 12 de Octubre (i+12), Department of Nephrology, Madrid, Spain.
⁵ Instituto de Investigación Hospital 12 de Octubre (i+12), Department of Nephrology, Madrid, Spain; Complutense University, Department of Medicine, Madrid, Spain.

Review

Ricard Cervera et al. Autoimmun Rev. 2019 Dec.

. 2019 Dec;18(12):102406.

doi: 10.1016/j.autrev.2019.102406. Epub 2019 Oct 22.

¹ Department of Autoimmune Diseases, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Catalonia, Spain. Electronic address: rcervera@clinic.cat.
² Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
³ Department of Autoimmune Diseases, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Catalonia, Spain.
⁴ Instituto de Investigación Hospital 12 de Octubre (i+12), Department of Nephrology, Madrid, Spain.
⁵ Instituto de Investigación Hospital 12 de Octubre (i+12), Department of Nephrology, Madrid, Spain; Complutense University, Department of Medicine, Madrid, Spain.

No abstract available

Publication types